Cardiovascular outcomes trials with glucagon‐like peptide‐1 receptor agonists: A comparison of study designs, populations and results

Despite treatment advances leading to improved outcomes over the past 2 decades, cardiovascular (CV) disease (CVD) remains the leading cause of morbidity and mortality in people with diabetes. People with type 2 diabetes (T2D) have a 2‐ to 4‐fold increased risk of CVD and CV death. Individuals with...

Descripción completa

Detalles Bibliográficos
Autores principales: Pantalone, Kevin M., Munir, Kashif, Hasenour, Clinton M., Atisso, Charles M., Varnado, Oralee J., Maldonado, Juan M., Konig, Manige
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754368/
https://www.ncbi.nlm.nih.gov/pubmed/32744372
http://dx.doi.org/10.1111/dom.14165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754368/
https://www.ncbi.nlm.nih.gov/pubmed/32744372
http://dx.doi.org/10.1111/dom.14165

Ejemplares similares